Literature DB >> 12735785

Benefits and risks of pharmacological treatments for essential tremor.

Kelly E Lyons1, Rajesh Pahwa, Cynthia L Comella, Mahmood S Eisa, Rodger J Elble, Stanley Fahn, Joseph Jankovic, Jorge L Juncos, William C Koller, William G Ondo, Kapil D Sethi, Matthew B Stern, Caroline M Tanner, Ron Tintner, Ray L Watts.   

Abstract

Essential tremor can cause significant functional disability in some patients. The arms are the most common body part affected and cause the most functional disability. The treatment of essential tremor includes medications, surgical options and other forms of therapy. Presently there is no cure for essential tremor nor are there any medications that can slow the progression of tremor. Treatment for essential tremor is recommended if the tremor causes functional disability. If the tremor is disabling only during periods of stress and anxiety, propranolol and benzodiazepines can be used during those periods when the tremor causes functional disability. The currently available medications can improve tremor in approximately 50% of the patients. If the tremor is disabling, treatment should be initiated with either primidone or propranolol. If either primidone or propranolol do not provide adequate control of the tremor, then the medications can be used in combination. If patients experience adverse effects with propranolol, occasionally other beta-adrenoceptor antagonists (such as atenolol or metoprolol) can be used. If primidone and propranolol do not provide adequate control of tremor, occasionally the use of benzodiazepines (such as clonazepam) can provide benefit. Other medications that may be helpful include gabapentin or topiramate. If a patient has disabling head or voice tremor, botulinum toxin injections into the muscles may provide relief from the tremor. Botulinum toxin in the hand muscles for hand tremor can result in bothersome hand weakness and is not widely used. There are other medications that have been tried in essential tremor and have questionable efficacy. These drugs include carbonic anhydrase inhibitors (e.g. methazolamide), phenobarbital, calcium channel antagonists (e.g. nimodipine), isoniazid, clonidine, clozapine and mirtazapine. If the patient still has disabling tremor after medication trials, surgical options are usually considered. Surgical options include thalamotomy and deep brain stimulation of the thalamus. These surgical options provide adequate tremor control in approximately 90% of the patients. Surgical morbidity and mortality for these procedures is low. Deep brain stimulation and thalamotomy have been shown to have comparable efficacy but fewer complications have been reported with deep brain stimulation. In patients undergoing bilateral procedures deep brain stimulation of the thalamus is the procedure of choice to avoid adverse effects seen with bilateral ablative procedures. The use of medication and/or surgery can provide adequate tremor control in the majority of the patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735785     DOI: 10.2165/00002018-200326070-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  127 in total

Review 1.  Pharmacologic treatment of essential tremor.

Authors:  W C Koller; A Hristova; M Brin
Journal:  Neurology       Date:  2000       Impact factor: 9.910

Review 2.  Botulinum toxin: evidence-based medicine criteria in rare indications.

Authors:  W H Jost; A Kohl
Journal:  J Neurol       Date:  2001-04       Impact factor: 4.849

Review 3.  The mechanism of action of tetanus and botulinum neurotoxins.

Authors:  C Montecucco; G Schiavo; O Rossetto
Journal:  Arch Toxicol Suppl       Date:  1996

4.  beta-Adrenoreceptor antagonists in essential tremor.

Authors:  D Jefferson; P Jenner; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-10       Impact factor: 10.154

5.  Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial.

Authors:  W Ondo; C Hunter; K D Vuong; K Schwartz; J Jankovic
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

6.  Clozapine in the treatment of tremor.

Authors:  H Pakkenberg; B Pakkenberg
Journal:  Acta Neurol Scand       Date:  1986-03       Impact factor: 3.209

7.  Dose-response relationship of propranolol in the treatment of essential tremor.

Authors:  W C Koller
Journal:  Arch Neurol       Date:  1986-01

8.  Double-blind comparison of primidone and phenobarbital in essential tremor.

Authors:  E Sasso; E Perucca; S Calzetti
Journal:  Neurology       Date:  1988-05       Impact factor: 9.910

9.  Time course of a single oral dose of propranolol in essential tremor.

Authors:  W C Koller; V L Royse
Journal:  Neurology       Date:  1985-10       Impact factor: 9.910

10.  Essential tremor: clinical correlates in 350 patients.

Authors:  J S Lou; J Jankovic
Journal:  Neurology       Date:  1991-02       Impact factor: 9.910

View more
  21 in total

1.  Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases.

Authors:  Angelo Franzini; Roberto Cordella; Giuseppe Messina; Carlo Efisio Marras; Luigi Michele Romito; Alberto Albanese; Michele Rizzi; Nardo Nardocci; Giovanna Zorzi; Edvin Zekaj; Flavio Villani; Massimo Leone; Orsola Gambini; Giovanni Broggi
Journal:  Neurol Sci       Date:  2012-01-24       Impact factor: 3.307

2.  Impact of advancing age on post-operative complications of deep brain stimulation surgery for essential tremor.

Authors:  Terence Verla; Andrew Marky; Harrison Farber; Frank W Petraglia; John Gallis; Yuliya Lokhnygina; Beth Parente; Patrick Hickey; Dennis A Turner; Shivanand P Lad
Journal:  J Clin Neurosci       Date:  2015-02-07       Impact factor: 1.961

Review 3.  Pharmacotherapy of essential tremor : an overview of existing and upcoming agents.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients.

Authors:  Angelo Franzini; Roberto Cordella; Giuseppe Messina; Carlo Efisio Marras; Luigi Michele Romito; Francesco Carella; Alberto Albanese; Michele Rizzi; Nardo Nardocci; Giovanna Zorzi; Edvin Zekay; Giovanni Broggi
Journal:  J Neural Transm (Vienna)       Date:  2011-05-20       Impact factor: 3.575

Review 5.  The treatment of movement disorders by deep brain stimulation.

Authors:  Hong Yu; Joseph S Neimat
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 6.  [Tremor. Differential diagnosis and treatment].

Authors:  H Wilms; J Raethjen
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

Review 7.  Deep brain stimulation and tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 8.  Closed-loop brain-machine-body interfaces for noninvasive rehabilitation of movement disorders.

Authors:  Frédéric D Broccard; Tim Mullen; Yu Mike Chi; David Peterson; John R Iversen; Mike Arnold; Kenneth Kreutz-Delgado; Tzyy-Ping Jung; Scott Makeig; Howard Poizner; Terrence Sejnowski; Gert Cauwenberghs
Journal:  Ann Biomed Eng       Date:  2014-05-15       Impact factor: 3.934

9.  Key issues in essential tremor genetics research: Where are we now and how can we move forward?

Authors:  Claudia M Testa
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-01-22

10.  Tremor analysis with wearable sensors correlates with outcome after thalamic deep brain stimulation.

Authors:  Dayle Rüegge; Sujitha Mahendran; Lennart H Stieglitz; Markus F Oertel; Roger Gassert; Olivier Lambercy; Christian R Baumann; Lukas L Imbach
Journal:  Clin Park Relat Disord       Date:  2020-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.